CANNDOC
Israeli licensed medical cannabis grower and supplier operating since 2008, now a subsidiary of InterCure.
Last updated September 26, 2026
AI crawler reads
4requests
1companies- Anthropic4
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
CANNDOC (Hebrew: קנדוק) is an Israeli company engaged in the licensed cultivation, production and supply of medical cannabis under the supervision of Israel's Ministry of Health. It began operating in 2008, when the Ministry's Medical Cannabis Unit (Yakar) granted it one of the first three licenses in Israel to grow and supply medical cannabis to licensed patients. For roughly its first two years the company provided cannabis to patients at no cost. After the Ministry introduced regulation of medical cannabis in 2010, CANNDOC became a limited liability company in March 2010 and began supplying products for a fixed monthly fee of 360 shekels, independent of product type or quantity. The company cultivates multiple strains of Pharma Grade medical cannabis and supplies them to patients on a monthly basis, both directly and through pharmacies. It also engages in research and development of new cannabis-based medical products. In 2018 CANNDOC announced that it was cultivating its strains to the highest standards and could produce them under IMC-GMP (Good Manufacturing Practice) certification, allowing entry into pharmacies where they are sold to patients by prescription under the Ministry's new regulatory framework. In June 2018 CANNDOC became a subsidiary of InterCure, which is traded on the Tel Aviv Stock Exchange and other exchanges. Following the acquisition, InterCure appointed former Israeli Prime Minister Ehud Barak as chairman of the company. In April 2019 CANNDOC announced the establishment of a second growing facility in southern Israel, in addition to its northern facility, aiming for maximum production capacity of up to 100 tons of medical cannabis per year. CANNDOC has pursued international partnerships. In May 2019 it reported a strategic partnership with a Canadian company owning an indoor medical cannabis cultivation and production facility, under which CANNDOC products would be produced under the CANNDOC brand and distributed to patients across Canada. In June 2019 it reported a strategic partnership with a Danish company holding a medical cannabis cultivation license in Denmark, with an indoor facility including laboratories, trial rooms and an extraction facility; CANNDOC products would be produced under the CANNDOC brand and distributed to pharmacies in various EU countries. In September 2019 it reported a strategic partnership with S.L.A. (part of the Teva group) for distribution of CANNDOC products to pharmacies throughout Israel from S.L.A.'s logistics center in Shoham. In January 2020 it reported strategic cooperation with Canada's Tilray (Nasdaq: TLRY) to import up to 2.5 tons of GMP-standard medical cannabis from Tilray's Portugal facility for marketing in Israeli pharmacies, and to export up to 5 tons of GMP-standard medical cannabis to Tilray for marketing under the Tilray brand, subject to Israeli export permits; CANNDOC also received 7.5-year exclusivity for selling Tilray cannabis products in Israel. In November 2019 the company reported starting a clinical trial of cannabis treatment for children on the autism spectrum, involving 100 patients over 24 months at Shamir Medical Center (Assaf Harofeh Hospital). CANNDOC's leadership has changed several times: Roy Zarchia served as CEO; in February 2019 Major General (res.) Nitzan Alon was appointed CEO with Zarchia as deputy; in April 2019 Ehud Barak, chairman of parent InterCure, also became chairman of CANNDOC, with Alon Granot as vice chairman; in August 2019 Nitzan Alon stepped down and Alon Granot became CEO; in December 2020 Granot stepped down as CEO and continued as a director responsible for M&A, with InterCure CEO Alexander Rabinovich also appointed CEO of CANNDOC.
History
CANNDOC began its operations in 2008 after Israel's Ministry of Health Medical Cannabis Unit (Yakar) granted it one of the first three licenses in the country to grow and supply medical cannabis to licensed patients. For approximately two years, the company cultivated medical cannabis and provided it to patients free of charge. In 2010, the Ministry of Health introduced regulation of medical cannabis in Israel, allowing the company to supply medical cannabis products to patients for a fixed monthly fee of 360 shekels, regardless of product type or quantity. In March 2010, CANNDOC became a limited liability company. Since then, CANNDOC has focused on cultivating multiple strains of Pharma Grade medical cannabis and supplying them to patients on a monthly basis, both directly and through pharmacies. It also conducts research and development of new cannabis-based medical products. In 2018, the company announced that it was cultivating its strains to the highest standards and could produce them under IMC-GMP (Good Manufacturing Practice) certification, enabling entry into pharmacies where products are sold to patients by prescription under the Ministry's new regulatory framework. In June 2018, CANNDOC became a subsidiary of InterCure, which is traded on the Tel Aviv Stock Exchange and other exchanges. Following this, InterCure appointed former Israeli Prime Minister Ehud Barak as chairman of the company. In April 2019, CANNDOC announced the establishment of a second growing facility in southern Israel, in addition to its northern facility, aiming for maximum production capacity of up to 100 tons of medical cannabis per year. Leadership changes have been frequent. Roy Zarchia served as CEO. In February 2019, Major General (res.) Nitzan Alon was appointed CEO, with Zarchia becoming deputy CEO. In April 2019, Ehud Barak, chairman of parent InterCure, also became chairman of CANNDOC, and Alon Granot was appointed vice chairman. In August 2019, Nitzan Alon retired from managing the company, and Alon Granot was appointed CEO in his place. In December 2020, Granot retired as CEO and continued to serve as a director responsible for mergers and acquisitions. Alexander Rabinovich, CEO of parent InterCure, was also appointed CEO of CANNDOC. CANNDOC has formed several strategic partnerships. In May 2019, it reported a strategic partnership with a Canadian company owning an indoor facility for growing and producing medical cannabis in Canada; under the partnership, CANNDOC would produce products under the CANNDOC brand for distribution to patients across Canada. In June 2019, it reported a strategic partnership with a Danish company holding a license to grow medical cannabis in Denmark; the Danish partner owns an indoor facility including laboratories, trial rooms and an extraction facility. Under the partnership, CANNDOC would produce products under the CANNDOC brand and distribute them to pharmacies in various EU countries. In September 2019, it reported a strategic partnership with S.L.A. (part of the Teva group), under which S.L.A. would distribute CANNDOC products to pharmacies throughout Israel from its logistics center in Shoham, one of the largest and most advanced in the pharmaceutical industry. In January 2020, it reported strategic cooperation with Canada's Tilray (Nasdaq: TLRY), under which CANNDOC would import up to 2.5 tons of GMP-standard medical cannabis from Tilray's Portugal facility and market it in Israeli pharmacies. In addition, CANNDOC would export up to 5 tons of GMP-standard medical cannabis to Tilray for marketing under the Tilray brand, subject to receiving an export permit from Israel. CANNDOC also received exclusivity for 7.5 years to sell Tilray's cannabis products in Israel. In November 2019, the company reported starting a clinical trial of cannabis treatment for children on the autism spectrum. The trial was to involve 100 patients and last 24 months at Shamir Medical Center (Assaf Harofeh Hospital).
- 2020
In January, reports strategic cooperation with Tilray for import/export and 7.5-year exclusivity in Israel.
- 2020
In December, Alon Granot steps down as CEO; Alexander Rabinovich appointed CEO.
- 2019
In February, Nitzan Alon appointed CEO.
- 2019
In April, announces second growing facility in southern Israel targeting up to 100 tons annual capacity.
- 2019
In May, reports strategic partnership with a Canadian company for CANNDOC-branded products in Canada.
- 2019
In June, reports strategic partnership with a Danish company for EU distribution.
- 2019
In August, Nitzan Alon steps down; Alon Granot becomes CEO.
- 2019
In September, reports distribution partnership with S.L.A. (Teva group).
- 2019
In November, starts clinical trial for children on the autism spectrum.
- 2018
Announces IMC-GMP certification capability for pharmacy distribution.
Products and positioning
Licensed Israeli medical cannabis producer and supplier operating under Ministry of Health supervision, with international distribution partnerships.
Pharma Grade medical cannabis strains
Multiple strains cultivated for medical use and supplied monthly to patients.
IMC-GMP certified medical cannabis
Products manufactured under Good Manufacturing Practice standards for pharmacy distribution.
Cannabis-based medical products (R&D)
New products under research and development.
Recent events
Charlotte’s Web signs exclusive distribution deal for Israel[4]
Charlotte’s Web announced that its wholly owned subsidiary signed an exclusive distribution agreement in Israel with InterCure, which owns Canndoc. Selected Charlotte’s Web hemp extract wellness products are to be made available through Canndoc or another InterCure subsidiary.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/canndoc · Editorial policy · How profiles are compiled